Jin Y, Fang Y, Yao Y. Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma". Haematologica; https://doi.org/10.3324/haematol.2026.301607 [Early view].